Genentech’s Hillsboro Oregon campus—Hillsboro Innovative Therapies (HIT)—serves as a critical hub for emerging cell & gene therapy manufacturing. Housed within a modern 75-acre facility just outside Portland, HIT is at the forefront of advancing cell and gene therapy medicines through accelerated clinical and commercial manufacturing capabilities, aligning with Genentech’s mission to bring transformative therapies to patients. To strengthen HIT’s capabilities in advanced therapy manufacturing, we are establishing a senior engineering leadership role focused on process engineering, drug product engineering, and cell therapy manufacturing equipment. The Head of Process and Drug Product Engineering will define and lead the strategy for equipment evolution, oversee lifecycle management, and enable innovative, scalable systems that support ongoing clinical manufacturing as well as future commercial production. This role will also represent HIT within the Genentech and Roche global network to align equipment strategy and influence enterprise-level engineering standards for cell therapy manufacturing.